ARROWHEAD PHARMACEUTICALS, INC. (ARWR) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-04-24

Key Insights

Chief Medical Officer James Hamilton executed a pre-planned stock sale of 10,000 shares at $75.00-$75.13 per share on April 23, 2026, pursuant to a Rule 10b5-1 trading plan, indicating a disciplined divestment strategy rather than opportunistic selling.
Hamilton retains 226,958 shares of beneficial ownership following the transaction, representing substantial continued investment in the company and confidence in long-term prospects despite the near-term sale.
The use of a 10b5-1 trading plan demonstrates compliance with insider trading regulations and suggests the sale was predetermined rather than based on material non-public information, limiting negative inference for investors.

Want the newest filings?

This analysis covers the filing from 2026-04-24. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-04-24

CFO Daniel Joseph Apel executed three separate stock sales totaling 13,095 shares on 04/22/2026 through a Rule 10b5-1 trading plan, with sales prices ranging from $69.50 to $71.97, suggesting pre-planned, systematic diversification rather than sudden confidence loss.
The sales appear to be tax-related, as shares were sold to satisfy tax withholding obligations on vesting restricted stock units (RSUs), which is a routine insider transaction pattern rather than a bearish signal about company prospects.
Apel retained 162,905 shares of beneficial ownership following these sales, maintaining substantial equity stake in ARWR and indicating continued confidence in the company despite the diversification activity.
The use of a 10b5-1 trading plan demonstrates compliance with insider trading regulations and suggests the transactions were executed according to a predetermined schedule rather than based on non-public information or market timing concerns.

Filed: 2026-01-08

The reporting person, Patrick O'Brien, is the Chief Operating Officer of Arrowhead Pharmaceuticals, Inc. and is conducting transactions in the company's common stock.
O'Brien made multiple gifts of Arrowhead Pharmaceuticals stock, totaling 2,500 shares, to relatives on January 6, 2026.
Additionally, O'Brien was granted 75,000 restricted stock units, which will vest in four equal annual installments, further increasing his beneficial ownership of Arrowhead Pharmaceuticals stock.

Filed: 2026-01-08

Daniel Joseph Apel, the Chief Financial Officer of Arrowhead Pharmaceuticals, Inc. (ARWR), acquired 75,000 shares of the company's common stock on January 6, 2026, potentially signaling his confidence in the company's future performance.
The acquisition of shares by a key executive officer could be viewed positively by investors as it aligns his interests with those of the shareholders.
The reported transaction represents a 74.5% increase in Apel's direct beneficial ownership of ARWR, which may indicate his belief in the company's growth prospects.

Filed: 2026-01-08

James C. Hamilton, the Chief Medical Officer of Arrowhead Pharmaceuticals, acquired 75,000 shares of the company's common stock through restricted stock units that will vest over four years.
This transaction indicates Hamilton's continued commitment to the company and confidence in its future prospects.
The reported transaction is a typical equity-based compensation for a senior executive and does not suggest any significant changes in the company's operations or financial performance.

Filed: 2025-12-30

The reporting person, Mauro Ferrari, is a director of Arrowhead Pharmaceuticals, Inc. (ARWR) and has sold 7,530 shares of the company's common stock pursuant to a 10b5-1 trading plan.
The reporting person still holds a significant number of shares (69,053) following the reported transaction, indicating continued investment in the company.
The sale of shares was executed at a price of $70 per share, which may provide insight into the current market valuation of the company's stock.

Filed: 2025-12-30

The CEO Christopher Anzalone exercised 35,181 and 16,545 stock options, and subsequently sold 35,181 and 16,545 shares, indicating his confidence in the company's performance.
The options were exercised and sold pursuant to a 10b5-1 trading plan, suggesting pre-planned and structured insider transactions.
The CEO's remaining beneficial ownership of 3,805,926 shares demonstrates his substantial stake and alignment with shareholder interests.

Other reports for ARROWHEAD PHARMACEUTICALS, INC.

Current Report Quarterly Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.